{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:48:56Z","timestamp":1767865736628,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2021-I2M-1-045"],"award-info":[{"award-number":["2021-I2M-1-045"]}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2021-I2M-1-045"],"award-info":[{"award-number":["2021-I2M-1-045"]}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2021-I2M-1-045"],"award-info":[{"award-number":["2021-I2M-1-045"]}]},{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2021-I2M-1-045"],"award-info":[{"award-number":["2021-I2M-1-045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s43441-025-00743-9","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T22:09:07Z","timestamp":1739484547000},"page":"450-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes in Clinical Trials of Dermatological Drugs in Mainland China Between 2016 and 2022: A Narrative Review"],"prefix":"10.1007","volume":"59","author":[{"given":"Beibei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"743_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789\u2013858.","journal-title":"Lancet"},{"key":"743_CR2","first-page":"472","volume":"3","author":"D Peng","year":"2021","unstructured":"Peng D, Sun J, Wang J, et al. Burden of skin disease\u2014China, 1990\u20132019. CCDCW. 2021;3:472\u20135.","journal-title":"CCDCW"},{"key":"743_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394:1145\u201358.","journal-title":"Lancet"},{"key":"743_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/MOP.0000000000000792","volume":"31","author":"JH Wu","year":"2019","unstructured":"Wu JH, Cohen BA. The stigma of skin disease. Curr Opin Pediatr. 2019;31:509\u201314.","journal-title":"Curr Opin Pediatr"},{"key":"743_CR5","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.17nr02247","author":"M Jafferany","year":"2018","unstructured":"Jafferany M, Pastolero P. Psychiatric and psychological impact of chronic skin disease. Prim Care Companion CNS Disord. 2018. https:\/\/doi.org\/10.4088\/PCC.17nr02247.","journal-title":"Prim Care Companion CNS Disord"},{"key":"743_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/1346-8138.14338","volume":"45","author":"S Imafuku","year":"2018","unstructured":"Imafuku S, Zheng M, Tada Y, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45:805\u201311.","journal-title":"J Dermatol"},{"key":"743_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00403-024-03046-5","volume":"316","author":"Y Kong","year":"2024","unstructured":"Kong Y, Xing P, Huai P, et al. The burden of skin diseases in China: global burden of disease study 2019. Arch Dermatol Res. 2024;316:277.","journal-title":"Arch Dermatol Res"},{"key":"743_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875492","author":"H Ujiie","year":"2022","unstructured":"Ujiie H, Rosmarin D, Sch\u00f6n MP, et al. Unmet medical needs in chronic non-communicable inflammatory skin diseases. Front Med. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.875492.","journal-title":"Front Med"},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12247-022-09655-9","volume":"18","author":"S Chen","year":"2023","unstructured":"Chen S, Chen X, Liu M, et al. Regulation of generic drugs in China: progress and effect of the reform of the review and approval system. J Pharm Innov. 2023;18:340\u20138.","journal-title":"J Pharm Innov"},{"key":"743_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s11192-019-03313-7","volume":"122","author":"H Zhong","year":"2020","unstructured":"Zhong H, Ouyang D. The gap analysis between Chinese pharmaceutical academia and industry from 2000 to 2018. Scientometrics. 2020;122:1113\u201328.","journal-title":"Scientometrics"},{"key":"743_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12913-018-2875-6","volume":"18","author":"J Sun","year":"2018","unstructured":"Sun J, Hu CJ, Stuntz M, et al. A review of promoting access to medicines in China\u2014problems and recommendations. BMC Health Serv Res. 2018;18:125.","journal-title":"BMC Health Serv Res"},{"key":"743_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(17)30406-0","volume":"18","author":"M Wang","year":"2017","unstructured":"Wang M. Clinical trials and drug approvals continue to accelerate in China. Lancet Oncol. 2017;18:855.","journal-title":"Lancet Oncol"},{"key":"743_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2017.10","volume":"14","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Chen X-Y, Yang Z-M, et al. The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol. 2017;14:577\u201383.","journal-title":"Nat Rev Clin Oncol"},{"key":"743_CR14","unstructured":"The State Council of the People\u2019s Republic of China. Opinions of the State Council on the Reform of the Review and Approval Process for Drugs and Medical Devices (in Chinese), https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/zhuanti\/ypqxgg\/ggzhcfg\/20150818101201640.html (2015, accessed 30 September 2024)."},{"key":"743_CR15","unstructured":"General Office of the CPC Central Committee and the General Office of the State Council. Opinions on Deepening the Reform of the Evaluation and Approval Systems to Encourage Innovation on Drugs and Medical Devices [in Chinese], http:\/\/www.gov.cn\/zhengce\/2017-10\/08\/content_5230105.htm (2017, accessed 25 September 2022)."},{"key":"743_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13023-023-02684-8","volume":"18","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Pei Z, Hu A, et al. Analysis of incentive policies and initiatives on orphan drug development in China: challenges, reforms and implications. Orphanet J Rare Dis. 2023;18:220.","journal-title":"Orphanet J Rare Dis"},{"key":"743_CR17","unstructured":"People\u2019s Daily. National Major Scientific and Technological Special Project for \u201cSignificant New Drugs Development\u201d Achives Fruitful Results, https:\/\/www.gov.cn\/xinwen\/2019-08\/01\/content_5417723.htm (2019, accessed 28 November 2024)."},{"key":"743_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/d41573-022-00077-3","volume":"21","author":"X Su","year":"2022","unstructured":"Su X, Wang H, Zhao N, et al. Trends in innovative drug development in China. Nat Rev Drug Discov. 2022;21:709\u201310.","journal-title":"Nat Rev Drug Discov"},{"key":"743_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s43441-022-00472-3","volume":"57","author":"L Su","year":"2023","unstructured":"Su L, Liu S, Li G, et al. Trends and characteristics of new drug approvals in China, 2011\u20132021. Ther Innov Regul Sci. 2023;57:343\u201351.","journal-title":"Ther Innov Regul Sci"},{"key":"743_CR20","unstructured":"China Food and Drug Administration. Announcement of the State Food and Drug Administration on the information platform for drug clinical studies (no. 28) (in Chinese), https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20130906120001263.html?type=pc&m= (2013, accessed 29 September 2024)."},{"key":"743_CR21","unstructured":"National Medical Products Administration. Requirements for Registration Classification and Application Dossiers of Chemical Drugs (No. 44 of 2020) (in Chinese), https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20200630180301525.html?type=pc&m= (accessed 27 November 2024)."},{"key":"743_CR22","unstructured":"National Medical Products Administration. Requirements for Registration Classification and Application Dossiers of Biological Products (No. 43 of 2020) (in Chinese), https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20200630175301552.html?type=pc&m= (accessed 27 November 2024)."},{"key":"743_CR23","unstructured":"The Office of the State Council of China. Opinions of the General Office of the State Council on the Consistency Evaluation of the Quality and Efficacy of Generic Drugs [2016] No. 8. (in Chinese), https:\/\/www.gov.cn\/zhengce\/zhengceku\/2016-03\/05\/content_5049364.htm (2016, accessed 28 November 2024)."},{"key":"743_CR24","first-page":"497","volume":"14","author":"SS Patel","year":"2015","unstructured":"Patel SS, Huang KE, Fleischer AB, et al. Five-year trend in the number of dermatologic clinical drug trials registered on clinical trials.gov. J Drugs Dermatol. 2015;14:497\u2013500.","journal-title":"J Drugs Dermatol"},{"key":"743_CR25","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.apsb.2022.02.018","volume":"12","author":"H Hu","year":"2022","unstructured":"Hu H, Lu X, Xu H, et al. Analysis of new drug registration and review in China in 2021. Acta Pharm Sin B. 2022;12:2127\u20138.","journal-title":"Acta Pharm Sin B"},{"key":"743_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-981-97-1471-1_4","volume-title":"Biopharma in China: Innovation Trends and Dealmaking","author":"S Agten","year":"2024","unstructured":"Agten S, Wu B. Innovation in the Chinese Biopharma Sector: From Me-too to First-in-Class. In: Agten S, Wu B, editors. Biopharma in China: Innovation Trends and Dealmaking. Springer; 2024. p. 71\u201399."},{"key":"743_CR27","doi-asserted-by":"publisher","first-page":"12037","DOI":"10.3390\/ijerph182212037","volume":"18","author":"Y Hu","year":"2021","unstructured":"Hu Y, Chen S, Qiu F, et al. Will the volume-based procurement policy promote pharmaceutical firms\u2019 R&D investment in China? an event study approach. Int J Environ Res Public Health. 2021;18:12037.","journal-title":"Int J Environ Res Public Health"},{"key":"743_CR28","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1186\/s12889-021-11882-7","volume":"21","author":"N Wang","year":"2021","unstructured":"Wang N, Yang Y, Xu L, et al. Influence of Chinese national centralized drug procurement on the price of policy-related drugs: an interrupted time series analysis. BMC Public Health. 2021;21:1883.","journal-title":"BMC Public Health"},{"key":"743_CR29","doi-asserted-by":"publisher","first-page":"9415","DOI":"10.3390\/ijerph17249415","volume":"17","author":"L Chen","year":"2020","unstructured":"Chen L, Yang Y, Luo M, et al. The impacts of national centralized drug procurement policy on drug utilization and drug expenditures: the case of Shenzhen, China. Int J Environ Res Public Health. 2020;17:9415.","journal-title":"Int J Environ Res Public Health"},{"key":"743_CR30","doi-asserted-by":"publisher","first-page":"e054346","DOI":"10.1136\/bmjopen-2021-054346","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Yang Y, Xu L, et al. Impact of \u20184+7\u2019 volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China. BMJ Open. 2022;12:e054346.","journal-title":"BMJ Open"},{"key":"743_CR31","unstructured":"National Medical Products Administration. Guidelines for International Multicenter Drug Clinical Trials (Draft) (No. 2 of 2015) (in Chinese), https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20150130120001641.html?type=pc&m= (2015, accessed 28 November 2024)."},{"key":"743_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/cpt.61","volume":"97","author":"A Ramamoorthy","year":"2015","unstructured":"Ramamoorthy A, Pacanowski MA, Bull J, et al. Racial\/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97:263\u201373.","journal-title":"Clin Pharmacol Ther"},{"key":"743_CR33","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cts.12771","volume":"13","author":"C Lo","year":"2020","unstructured":"Lo C, Nguyen S, Yang C, et al. Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications. Clin Transl Sci. 2020;13:861\u201370.","journal-title":"Clin Transl Sci"},{"key":"743_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00403-022-02324-4","volume":"315","author":"JE Ferguson","year":"2023","unstructured":"Ferguson JE, Seger EW, White J, et al. Racial\/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review. Arch Dermatol Res. 2023;315:41\u201350.","journal-title":"Arch Dermatol Res"},{"key":"743_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","volume":"27","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340\u201357.","journal-title":"Exp Dermatol"},{"key":"743_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/2229-3485.179430","volume":"7","author":"P Shenoy","year":"2016","unstructured":"Shenoy P. Multi-regional clinical trials and global drug development. Perspect Clin Res. 2016;7:62\u20137.","journal-title":"Perspect Clin Res"},{"key":"743_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1052977","author":"N Huang","year":"2023","unstructured":"Huang N, Huang W, Luo Y, et al. China\u2019s drug clinical trial institution record-keeping system: qualification requirements for PI are the key. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1052977.","journal-title":"Front Pharmacol"},{"key":"743_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2133.2006.07153.x","volume":"154","author":"SM Langan","year":"2006","unstructured":"Langan SM, Bourke JF, Silcocks P, et al. An exploratory prospective observational study of environmental factors exacerbating atopic eczema in children. Br J Dermatol. 2006;154:979\u201380.","journal-title":"Br J Dermatol"},{"key":"743_CR39","doi-asserted-by":"publisher","first-page":"2568301","DOI":"10.1155\/2016\/2568301","volume":"2016","author":"X Wang","year":"2016","unstructured":"Wang X, Li L-F, Zhao D-Y, et al. Prevalence and clinical features of atopic dermatitis in China. Biomed Res Int. 2016;2016:2568301.","journal-title":"Biomed Res Int"},{"key":"743_CR40","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1097\/CM9.0000000000002172","volume":"135","author":"J Li","year":"2022","unstructured":"Li J, Mao D, Liu S, et al. Epidemiology of urticaria in China: a population-based study. Chin Med J (Engl). 2022;135:1369\u201375.","journal-title":"Chin Med J (Engl)"},{"key":"743_CR41","unstructured":"Xu L, Zhang L, Tian X, et al. Epidemiological research on inpatients with skin cancer in China (in Chinese). \u4e2d\u56fd\u5faa\u8bc1\u533b\u5b66\u6742\u5fd7 2020; 20: 1280\u20131283."},{"key":"743_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02240","author":"J Qu","year":"2019","unstructured":"Qu J, Huang Y, Lv X. Crisis of antimicrobial resistance in China: now and the future. Front Microbiol. 2019. https:\/\/doi.org\/10.3389\/fmicb.2019.02240.","journal-title":"Front Microbiol"},{"key":"743_CR43","first-page":"1101","volume":"4","author":"H Wang","year":"2022","unstructured":"Wang H. Current and future landscape of the antimicrobial resistance of nosocomial infections in China. CCDCW. 2022;4:1101\u20134.","journal-title":"CCDCW"},{"key":"743_CR44","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1111\/all.15287","volume":"77","author":"X Zhang","year":"2022","unstructured":"Zhang X, Song X, Zhang M, et al. Prevalence and risk factors of chronic urticaria in China: a nationwide cross-sectional study. Allergy. 2022;77:2233\u20136.","journal-title":"Allergy"},{"key":"743_CR45","doi-asserted-by":"publisher","first-page":"100610","DOI":"10.1016\/j.waojou.2021.100610","volume":"14","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Cai T, Chen H, et al. Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organ J. 2021;14:100610.","journal-title":"World Allergy Organ J"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00743-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:51:06Z","timestamp":1745434266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00743-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00743-9","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The findings and conclusions of this review are those of authors, not officially representing the Chinese Academy of Medical Sciences. Beibei Zhu, Jing Li, Qi Ni, and Xueyuan Yang are affiliated with Chinese Academy of Medical Sciences (CAMS) as healthcare professionals. Shuo Yang and Zheng Yin are employees of IQVIA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the content discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}